Pfizer Earnings Call: Pipeline Strength Amid COVID Reset

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...
Kalkine Media

Pfizer Inc (NYSE:PFE) Shock Echoes Russell 1000 index Watchers Track Next Moves

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts

Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

Pfizer vs. Merck Stock And JNJ

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer Reshapes Portfolio With Obesity Bet, Vaccine Deal And Pricing Shift

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The company signed a licensing deal with Novavax for access to its Matrix-M ...